Innate Immunity in Systemic Sclerosis Fibrosis: Recent Advances

Area of Science:

• Immunology
• Rheumatology
• Pathophysiology

Background:

• Systemic sclerosis (SSc) is an autoimmune disease with hallmarks of vasculopathy, immune activation, and fibrosis.
• The precise role of innate immunity in SSc pathogenesis, particularly in disease initiation, remains incompletely understood.
• While macrophages and type I interferon are implicated, recent research highlights novel innate immune players in SSc.

Purpose of the Study:

• To review the evidence for innate immune processes in systemic sclerosis (SSc) development.
• To emphasize the role of innate immunity in the initiation of SSc pathology.
• To discuss emerging therapeutic strategies targeting innate immunity in SSc.

Main Methods:

• Literature review of recent studies on innate immunity in systemic sclerosis.
• Analysis of the roles of pathogen-recognition receptors, DAMPs, ILCs, and pDCs in SSc.
• Synthesis of evidence linking innate immune pathways to SSc vasculopathy and fibrosis.

Main Results:

• Innate immune cells and signaling pathways are integral to SSc pathogenesis.
• Novel innate immune players, including innate lymphoid cells and plasmacytoid dendritic cells, contribute to SSc.
• Innate immunity plays a critical role in the initiation and progression of SSc, including fibrosis.

Conclusions:

• Innate immunity is a key driver of systemic sclerosis (SSc) pathogenesis.
• Understanding novel innate immune pathways provides insights into SSc initiation and progression.
• Modulating innate immune cells and signaling represents a promising therapeutic avenue for SSc.